A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
NCT07301229
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
DRUG:
HLX43 DOSE 1 (2.5 mg/kg)
DRUG:
HLX43 DOSE 2 (3.0 mg/kg)
Sponsor
Shanghai Henlius Biotech